Participant flow

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Source last updated 2024-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity. HBI-8000: Orally twice weekly

   id

   FG000

   title

   HBI-8000

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         18

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Protocol Violation

   4. reasons

      1. group Id

         FG000

         num Subjects

         27

      type

      Disease Progression

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         55

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         52

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice